# Special Issue

# **Personalized Nanomedicine**

## Message from the Guest Editors

The design of nanosystems for biomedical applications has experienced an exponential increase in the last few decades. Year by year, novel delivery systems are developed with the aim to become advanced medicines. A wide range of nanotechnology applications in the biomedical field have been developed for drug delivery, diagnostics and theranostics or regenerative medicine purposes. Nanomedicines could be advantageous as novel personalized therapies, since they can be designed tuning their properties depending on the final specific function; using tailored (or innovative) biomaterials, incorporating the required targeting mojeties and loading the appropriate active principle. thus enabling the desired therapeutic action at the target tissue or cell. Although multiple advantages are attributed to nanomedicines, the literature concerning the design of personalized therapies using systems at the nanometric scale is still limited. For this reason, this Special Issue was created to be a meeting point for all those scientists who work creating novel personalized therapies making use of nanosystems.

## **Guest Editors**

Dr. Cristina Fornaguera

GEMAT, Bioengineering Department, IQS School of Engineering, Universitat Ramon Llull, Barcelona, Spain

Dr. Maria José García Celma

Faculty of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain

## Deadline for manuscript submissions

closed (30 April 2019)



# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



### mdpi.com/si/8610

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm





# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



# About the Journal

## Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

### Editor-in-Chief

### Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

### **Author Benefits**

### **High Visibility:**

indexed within Scopus, PubMed, PMC, Embase, and other databases.

### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

